CMXHF
Price
$134.87
Change
+$0.08 (+0.06%)
Updated
Sep 3 closing price
Capitalization
65.6B
GBIO
Price
$5.75
Change
-$0.23 (-3.85%)
Updated
Sep 4, 02:03 PM (EDT)
Capitalization
40.28M
62 days until earnings call
Interact to see
Advertisement

CMXHF vs GBIO

Header iconCMXHF vs GBIO Comparison
Open Charts CMXHF vs GBIOBanner chart's image
CSL
Price$134.87
Change+$0.08 (+0.06%)
Volume$9.65K
Capitalization65.6B
Generation Bio
Price$5.75
Change-$0.23 (-3.85%)
Volume$200
Capitalization40.28M
CMXHF vs GBIO Comparison Chart in %
Loading...
CMXHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMXHF vs. GBIO commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMXHF is a Hold and GBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CMXHF: $134.87 vs. GBIO: $5.98)
Brand notoriety: CMXHF and GBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMXHF: 1514% vs. GBIO: 13%
Market capitalization -- CMXHF: $65.6B vs. GBIO: $40.28M
CMXHF [@Biotechnology] is valued at $65.6B. GBIO’s [@Biotechnology] market capitalization is $40.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMXHF’s FA Score shows that 1 FA rating(s) are green whileGBIO’s FA Score has 0 green FA rating(s).

  • CMXHF’s FA Score: 1 green, 4 red.
  • GBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, CMXHF is a better buy in the long-term than GBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMXHF’s TA Score shows that 4 TA indicator(s) are bullish while GBIO’s TA Score has 3 bullish TA indicator(s).

  • CMXHF’s TA Score: 4 bullish, 6 bearish.
  • GBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GBIO is a better buy in the short-term than CMXHF.

Price Growth

CMXHF (@Biotechnology) experienced а -2.89% price change this week, while GBIO (@Biotechnology) price change was -5.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.27%. For the same industry, the average monthly price growth was +7.08%, and the average quarterly price growth was +29.28%.

Reported Earning Dates

GBIO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CMXHF($65.6B) has a higher market cap than GBIO($40.3M). CMXHF YTD gains are higher at: -18.689 vs. GBIO (-43.585). CMXHF has more cash in the bank: 1.52B vs. GBIO (141M). GBIO has less debt than CMXHF: GBIO (85.3M) vs CMXHF (12B).
CMXHFGBIOCMXHF / GBIO
Capitalization65.6B40.3M162,779%
EBITDAN/A-69.92M-
Gain YTD-18.689-43.58543%
P/E Ratio21.86N/A-
RevenueN/A21.2M-
Total Cash1.52B141M1,081%
Total Debt12B85.3M14,068%
FUNDAMENTALS RATINGS
CMXHF: Fundamental Ratings
CMXHF
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
56
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
91
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CMXHFGBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
36%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
48%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
46%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CMXHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSTR26.310.73
+2.85%
L.B. Foster Company
CWAN20.200.01
+0.05%
Clearwater Analytics Holdings
PEPG1.19-0.01
-0.83%
PepGen
AMGN283.85-3.07
-1.07%
Amgen
KRP13.74-0.19
-1.36%
Kimbell Royalty Partners LP

CMXHF and

Correlation & Price change

A.I.dvisor tells us that CMXHF and CCCC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMXHF and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMXHF
1D Price
Change %
CMXHF100%
+0.06%
CCCC - CMXHF
26%
Poorly correlated
+1.99%
REGN - CMXHF
23%
Poorly correlated
-2.44%
NRIX - CMXHF
22%
Poorly correlated
+3.84%
GBIO - CMXHF
22%
Poorly correlated
N/A
VRDN - CMXHF
22%
Poorly correlated
+1.72%
More

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with CABA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
N/A
CABA - GBIO
46%
Loosely correlated
+8.28%
MGNX - GBIO
45%
Loosely correlated
+9.77%
OVID - GBIO
43%
Loosely correlated
+8.13%
SYRE - GBIO
43%
Loosely correlated
+1.08%
IDYA - GBIO
42%
Loosely correlated
+1.10%
More